Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.4 USD | -3.72% | -6.38% | +3.29% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 272M |
---|---|---|---|---|---|
Net income 2024 * | -101M | Net income 2025 * | -122M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.77
x | P/E ratio 2025 * |
-2.75
x | Employees | 59 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.48% |
Latest transcript on Inozyme Pharma, Inc.
1 day | -3.72% | ||
1 week | -6.38% | ||
Current month | -0.23% | ||
1 month | -0.90% | ||
3 months | -32.93% | ||
6 months | +19.89% | ||
Current year | +3.29% |
Managers | Title | Age | Since |
---|---|---|---|
Axel Bolte
FOU | Founder | 52 | 15-08-31 |
Doug Treco Treco
CEO | Chief Executive Officer | 66 | 20-04-30 |
Director of Finance/CFO | 48 | 22-03-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Doug Treco Treco
CEO | Chief Executive Officer | 66 | 20-04-30 |
Reinaldo Diaz
BRD | Director/Board Member | 70 | 16-12-31 |
Axel Bolte
FOU | Founder | 52 | 15-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.49% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 4.4 | -3.72% | 367,687 |
24-05-24 | 4.57 | +0.22% | 234,398 |
24-05-23 | 4.56 | -2.56% | 312,405 |
24-05-22 | 4.68 | -0.43% | 311,985 |
24-05-21 | 4.7 | -0.63% | 445,306 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.29% | 272M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+38.39% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- INZY Stock